Surface expression of stromal cell-derived factor-1 (SDF-1) on platelets is enhanced during ischaemic events and might play an important role in peripheral homing and myocardial repair. As SDF-1 effects are mediated through CXCR4/ CXCR7, we investigated platelet expression of SDF-1/CXCR4/CXCR7 in patients with coronary artery disease (CAD).
Introduction
Functional recovery and prognosis after acute coronary syndrome (ACS) are mainly driven by the extent of reperfusion injury and myocardial repair mechanisms. Stromal cell-derived factor (SDF)-1, also known as CXCL12, is critically involved in recruiting bone-marrow-derived stem cells to sites of vascular and myocardial injury. 1 Furthermore, it enhances endothelial differentiation of progenitor cells in vitro and reveals proangiogenic effects. 2 It has recently been shown that adherent platelets express, subsequently secrete and are able to bind SDF-1, thus supporting chemotaxis and migration of progenitor cells from bone marrow to peripheral circulation. 3, 4 Moreover, platelet surface expression of SDF-1 is elevated in patients with ACS, in particular ST-elevation myocardial infarction compared with patients suffering from stable coronary artery disease (CAD). 5, 6 Mobilization of endogenous progenitor cells in ischaemic tissue due to increased platelet SDF-1 levels correlates with left ventricular functional recovery in ACS patients as documented by magnetic resonance imaging. 7 Previously, a bispecific SDF-1-glycoprotein VI (GPVI) fusion protein was generated, which binds with high affinity to extracellular matrix proteins that become exposed after tissue injury. The administration of SDF-1-GPVI reduces infarct size, recruits bone-marrow cells, enhances capillary density, and preserves cardiac systolic function in vivo. 8 There has been cumulative evidence about the importance of the axis between SDF-1 and its cognate receptor CXCR4 for endothelial progenitor recruitment and functional recovery after myocardial ischaemia. 9, 10 CXCR4 is expressed in a broad range of tissues, including immune and central nervous systems, and mediates migration of resting leucocytes and haematopoietic progenitor cells in response to SDF-1 in a number of physiological processes. 11 -14 CXCR7 has previously been reported as a novel receptor for SDF-1. It is located in cells from different organs, including the central nervous and haematopoietic systems, heart, placenta, bone, vascular endothelium, and kidney. 15 -20 Its expression has been shown to be elevated in activated endothelial cells associated with tumours 21 and during hypoxia. 22 Compared with CXCR4, CXCR7
has a higher binding affinity for SDF-1. 23 These characteristics suggest that besides CXCR4, CXCR7 might be critically involved in SDF-1-mediated regulation of angiogenesis and stem cell trafficking.
Little is known about the expression of CXCR4 and -7 on platelets, and there are sparse data regarding the in vivo crosstalk between platelet-bound SDF-1, CXCR4, and CXCR7. Hence, the aim of the present study was to investigate differential regulation of SDF-1 -CXCR4/CXCR7 axis on the surface of platelets of patients with symptomatic CAD.
Subjects and methods

Patient characteristics and blood sampling
For the pilot study, blood was collected from 15 subjects in each groups of healthy volunteers, patients with stable CAD, and those with ACS. For the cohort study, blood samples were collected during percutaneous coronary intervention (PCI) and immediately analysed for surface expression of CXCR4, CXCR7, SDF-1, and glycoprotein Ib (GPlb) by flow cytometry. All subjects gave written informed consent. Patients were admitted to the department of cardiology of the University of Tübingen, Germany. We included 215 consecutive patients with symptomatic CAD (stable angina, n ¼ 112; ACS, n ¼ 103). ACS was defined as worsening of angina, acute myocardial infarction, or sudden cardiac death. An acute myocardial infarction (AMI) was diagnosed by a rise and/or fall of cardiac biomarker values [cardiac troponin (cTn)] with at least one value above the 99th percentile upper reference limit and with at least one of the following: symptoms of ischaemia, new or presumed new significant ST-segment-T-wave (ST -T) changes or new left bundle branch block, development of pathological Q waves in the ECG, imaging evidence of new loss of viable myocardium or new regional wall motion abnormality, or identification of an intracoronary thrombus by angiography. 24 The study was approved by the institutional ethics committee (270/2011BO1) and complies with the declaration of Helsinki and the good clinical practice guidelines.
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Surface expression by whole-blood flow cytometry
Platelets in whole blood were analysed for the surface expression of CXCR4, CXCR7, SDF-1 gating for the platelet-specific marker GPIb. Blood collected in citrate phosphate dextrose adenine was diluted 1:50 with phosphate-buffered saline (PBS; Gibco) and incubated with the respective conjugated antibodies-mouse monoclonal antihuman CXCR4-PE, mouse monoclonal anti-human CXCR7-PE, mouse monoclonal anti-human SDF-1-CFS (all from R&D systems) and mouse anti-human GPIb-fluorescein isothiocyanate (FITC) (Beckman Coulter) or their respective isotype controls (mouse IgG1-FITC, mouse IgG2bPE from R&D systems) for 30 min at room temperature (RT). After staining, the cells were fixed with 0.5% paraformaldehyde and analysed by flow cytometry (FACSCalibur flow cytometer Becton-Dickinson, Heidelberg, Germany).
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To analyse agonist-induced changes in surface expression of SDF-1, CXCR4, or CXCR7, platelets in whole blood were treated with thrombin receptor activating peptide (TRAP) (25 mM) or adenosine diphosphate (ADP) (100 mM) for 30 min at RT, and stained for the surface expression of SDF-1, CXCR4, and CXCR7. TRAP (SFLLRN) and ADP were procured from Sigma-Aldrich.
Immunofluorescence confocal microscopic analysis of stromal cell-derived factor-1, CXCR4 and CXCR7
Platelets in platelet-rich plasma (PRP) were fixed with 1% paraformaldehyde, applied to 0.01% poly-L-lysine-coated coverslips, and permeabilized with 0.3% Triton X-100. 
Enzyme-linked immunosorbent assay
Plasma levels of SDF-1 were determined in the majority of enrolled patients (n ¼ 160) simultaneously with the flow cytometry analysis using a commercially available enzyme-linked immunosorbent assay kit according to the manufacturer's guidelines (R&D Systems, Minneapolis, MN, USA). The lower detection limit of this assay is 18 pg/mL. Ethylenediaminetetraacetic acid plasma probes were centrifuged for 15 min at 10 000 g within 30 min of collection. Probes were aliquoted and stored at 2808C until analysis.
Follow-up
During PCI, we investigated left ventricular ejection fraction (LVEF)% by laevo-cardiography. Intra-hospital course of LVEF% was evaluated in ACS patients using transthoracic echocardiography during a median of 5 days and at a 3-month follow-up. Two-dimensional echo LVEF was assessed using Simpson's biplane method of discs by manual planimetry of the endocardial border in end-diastolic and end-systolic frames. 31 
Statistical analysis
All statistical analyses were performed using SPSS version 18.0 (SPSS, Inc., Chicago, IL, USA). Normally distributed data were compared using independent Student's t-test. Non-parametric data, including median fluorescence intensities (MFIs), were compared using the Mann -Whitney U test. Correlations were assessed by Spearman's rank correlation coefficient (r). MFIs are presented as median values and 25th and 75th percentiles. Percentage LVEF values are presented as mean values + standard deviation (SD). Analysis of variance (ANOVA), using a general linear model (GLM) with repeated-measures and Greenhouse-Geisser method, was used at each time point (baseline, 5 days, and 3 months) to examine the differences between patients who showed CXCR7 levels above (.) or below (≤) the median. Pairwise comparisons (paired t-tests) were applied as post hoc tests only when ANOVA revealed overall significant differences. General linear models were established using univariate analysis of covariates to show independent associations of CXCR4 and CXCR7 levels after normalization for GPIb (CD42b) receptor count. Variables entered into the model included clinical risk factors, ACS, atrial fibrillation, platelet count, LVEF%, and cardiovascular co-medication. Additionally, impact of CXCR7 receptor expression on LVEF% recovery at 3 months was evaluated after adjustment for cardiovascular risk factors and maximum troponin release.
Results
Platelets express stromal cell-derived factor-1 receptors CXCR4 and CXCR7
Stromal cell-derived factor-1 is an essential regulatory factor governing platelet progenitor cell interactions and thereby platelet-driven repair mechanisms. 3,28,32 -35 Binding of SDF-1 to its receptors CXCR4 and CXCR7 modulates chemotaxis, migration, and survival of diverse cell types. 36 -38 In the pilot cohort of n ¼ 15 per group of patients with ACS, stable CAD, and healthy volunteers, we investigated platelet expression and localization of SDF-1 receptors. Both CXCR4 and CXCR7 are expressed in human platelets derived from healthy subjects and from stable CAD and ACS patient subpopulations, as evidenced by immunoblot and corresponding densitometric analysis ( Figure 1A ) , immunofluorescence confocal microscopy ( Figure 1B) , and also on platelet surface as verified by flow cytometry ( Figure 1C) . Expression of SDF-1 and its receptors CXCR4 and CXCR7 was significantly higher in ACS patients compared with patients with stable CAD ( Figure 1A , bar diagram showing densitometric analysis). Intracellular localization of these two receptors shows that CXCR4 was primarily localized towards platelet periphery on the plasma membrane under resting conditions, whereas CXCR7 was distributed both in the cytoplasm ( Figure 1B ) and in plasma membrane. Even though platelet activation resulted in substantial enhancement in surface expression of SDF-1, the surface exposure of CXCR4 and CXCR7 was not altered to a significant extent following activation by ADP or TRAP when compared with resting conditions ( Figure 1C) . Thereby, our data show that CXCR4 and CXCR7 are constitutively expressed in human platelets. (Figure 2A and B) .
Patients with ACS were further subdivided into patients with NSTEMI/STEMI (n ¼ 55), or troponin I-negative ACS (Tn 2 -ACS) (n ¼ 48). There was no significant difference between these ACS subgroups (Mann-Whitney U test P ¼ 0.052) and higher expression of CXCR7 levels in any of these subgroups compared with stable CAD patients (median 22.1, 25th; 75th percentile 14.8; 26.9, P ¼ 0.01 for NSTEMI/STEMI and median 17.7, 25th; 75th percentile 13.3; 27.0, P ¼ 0.09 for Trop-ACS compared with median 15.3, 25th; 75th percentile 13.1; 21.5 for stable CAD). CXCR4 and CXCR7 surface expression on platelets showed a moderate correlation (r ¼ 0.272, P , 0.001). Additionally, plateletbound SDF-1 correlated moderately with CXCR4 (n ¼ 215, r ¼ 0.273, P , 0.001), however strongly with CXCR7 expression levels (n ¼ 215, r ¼ 0.454, P , 0.001) ( Figure 3) . Next, we evaluated associations between surface expression of CXCR4 and CXCR7 and cardiovascular risk factors, cardiovascular comorbidities including atrial fibrillation, co-medication, and platelet count. In univariate analysis of covariance, no significant interrelations except for ACS vs. stable CAD on CXCR7 surface expression and use of beta blockers on CXCR4 surface expression could be shown (Tables 2 and 3) . Thus, ACS was independently associated with enhanced CXCR7 levels but not with CXCR4 levels. Plasma SDF-1 levels were measured by ELISA in 160 patients. Platelet CXCR4 and -7 levels did not correlate with plasma SDF-1 levels (Spearman's rank coefficient 0.15, P ¼ 0.065 and 0.08, P ¼ 0.317, respectively). In a separate analysis of 125 patients, we did not find a significant correlation between serum cholesterol levels and platelet CXCR4 and CXCR7 surface expression (data not shown). Additionally, there was no correlation between either platelet-bound CXCR4 or -7 expression and maximum troponin release in ACS patients (Spearman's rank coefficient 20.125; P ¼ 0.2 and 20.082; P ¼ 0.4, respectively, data not shown).
Follow-up of left ventricular ejection fraction
As SDF-1/CXCR4/CXCR7 is associated with myocardial repair mechanisms following reperfusion on the ischaemic myocardium, we performed follow-up of LVEF in ACS patients of the prospective cohort at 5 days (intra-hospital stay) and after 3 months to assess a possible influence of CXCR4 and CXCR7 surface expression of platelets on LVEF% recovery after myocardial injury. Interestingly, we found a significant association of CXCR7 surface expression on absolute changes in LVEF% at 5 days and after 3 months of follow-up (46.2 + 10.7, 49.8 + 9.5, 53.7 + 9.09; P ¼ 0.003 for CXCR7 . median vs. 52.1 + 9.5, 51.5 + 9.0, 49.9 + 12.7; P ¼ 0.21 for CXCR7 ≤ median) ( Figure 4 ). There was no significant association of platelet CXCR4 levels on Platelet SDF-1 -CXCR4/CXCR7 in acute coronary syndrome course of LVEF%. In univariate analysis of covariance, CXCR7 expression levels greater than median and smoking were independently associated with the relative change of LVEF% ( Table 4) .
Discussion
The major findings of the present study are (i) CXCR4 and CXCR7 are constitutively expressed in human platelets in healthy subjects and patients with CAD; (ii) platelet surface expression of CXCR7 is elevated in patients with ACS when compared with patients with stable CAD; (iii) surface expression of CXCR7 significantly correlates with surface expression of SDF-1; (iv) high CXCR7 levels are associated with improvement of LVEF% after ACS. Platelets have previously been found to be a major source for SDF-1. 3, 33 Platelet surface expression of SDF-1 is up-regulated and correlates with plasma SDF-1 levels in ACS patients. 5 Recent studies have shown that the SDF-1-CXCR4 interaction is important for the homing of bone-marrow-derived stem cells to damaged tissue. Moreover, SDF-1 plays a crucial role in trafficking of CXCR4 + bone-marrowderived cells into peripheral blood and their recruitment to damaged organs in vivo. Recently, CXCR7 has been identified as another specific scavenger or decoy receptor for SDF-1 (CXCL12) and CXCL11, mediating ligand internalization. 17 In contrast to CXCR4, CXCR7 fails to induce typical chemokine responses. 17 There is a crosstalk between CXCR4 and CXCR7 and expression of CXCR7 induces conformational re-arrangements within pre-existing CXCR4/G(alphai) protein complexes and impairs CXCR4-promoted G(alphai)-protein activation and calcium responses. 39 Differential expression patterns and effects mediated by CXCR4 and CXCR7 have been described previously in diverse cell types. SDF-1-mediated migration of progenitor cells has been found dependent on CXCR4, while CXCR7 is found to be essential for progenitor cell adhesion and SDF-1-induced cell survival.
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CXCR7 permanently cycles between the plasma membrane and intracellular compartments both in the presence and in the absence of its ligand SDF-1. It may scavenge and sequester SDF-1, thus generating gradients of SDF-1 that lead to differential signalling by CXCR4. 41, 42 Whereas CXCR4 experiences down-regulation, internalization, and degradation following incubation with SDF-1,
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CXCR7 undergoes a dynamic internalization and time-dependent externalization in response to SDF-1. 29 To date, no data exist on the differential expression of platelet CXCR4/-7 in ACS, its correlation with platelet-bound SDF-1, and its possible regulatory impact on myocardial repair mechanisms. Here, we report, for the first time, that platelet CXCR7 surface expression is significantly increased in patients with ACS compared with patients with stable CAD and it correlates well with platelet-bound SDF-1 expression. In contrast, we did not observe significantly enhanced expression of CXCR4 in ACS patients vs. stable CAD patients. According to previous results showing that CXCR7 expression is mainly unaffected by SDF-1 incubation, 44 hypoxia-induced enhanced surface expression of CXCR7 might prevail in the setting of ACS. In addition, we found an independent association of CXCR7 expression on longterm improvement of LVEF. Previously, it has been shown that platelet SDF-1 expression has a significant impact on myocardial function recovery in ACS. 7 The present findings suggest a potential role of CXCR7 in mediating these effects. Of note, neutralization of either CXCR4 or CXCR7 impairs the improved therapeutic potential of hypoxia preconditioned mesenchymal stem cells, indicating the importance of CXCR4 and CXCR7 in repair mechanisms after organ ischaemia. 44 Ambivalent mechanisms involving CXCR4 after ischaemia/reperfusion injury have been described previously. Thus, CXCR4 is critically involved in endogenous repair mechanisms after MI by means of inflammatory/progenitor cell recruitment and neovascularization, whereas its deficiency reduces infarct size and supports protection against hypoxic stress. 45 CXCR7 blockage can interfere with SDF-1/CXCR4-induced human endothelial progenitor cell adhesion to active endothelium and trans-endothelial migration. 46 Additionally, CXCR7 has been reported to exclusively mediate human progenitor cell survival but not proliferation.
Previous reports suggest a potential role of SDF-1 -CXCR4-CXCR7 axis in progenitor cell survival after hypoxia-induced organ injury. Different confounders have been reported to possibly influence the axis between SDF-1 and its cellular receptors, including hypercholesterolaemia, platelet count/platelet size, and atrial fibrillation. 47 -49 In analyses of the present cohort, we did not observe any significant relationship with these parameters. In a previous study, CXCR4 was found decreased in the megakaryocytic lineage in essential thrombocythemia (ET), mainly due to a reduced CXCR4 expression resulting in an altered platelet response to SDF-1. 50 However, none of the enrolled patients in the present study were diagnosed for treated or untreated ET. We further evaluated plasma levels of SDF-1 in 160 patients, but did not find a significant correlation between platelet CXCR4 and -7 surface expression with plasma SDF-1 levels. This is in accordance with previous reports in different cell lines, showing that high plasma SDF-1 levels do not necessarily correlate with CXCR4 expression levels. Regarding the correlation of plasma SDF-1 and CXCR7, there is a lack of evidence, so far. We reported previously that platelet surface expression of SDF-1 poorly correlates with plasma SDF-1 in CAD patients (r ¼ 0.084, P ¼ 0.045). 5 The mechanism behind this poor correlation is barely speculative and warrants further investigation. However, a probable explanation for these observations might be that platelet-derived SDF-1 acts in an autocrine way to bind to its surface receptor and regulates relative receptor expression and internalization. Besides, plasma SDF-1 is highly vulnerable to partial or total degradation by various proteases (e.g. elastase, MMP2, MMP9, cathepsin G, CD26/DPP4 and carboxypeptidase N) in circulation and therefore might account for the lack of correlation with cellular receptor expression. 51, 52 In the present study, we found high CXCR7 levels to be independently associated with improvement of LVEF% after ACS, as measured by echocardiographic parameters. Previously, we found that platelet-SDF-1 is associated with hemodynamic function and infarct size using cardiac magnetic resonance (MR) in patients with AMI. 7 Similarly, further systematic studies defining infarct size by standard MRI parameters would be needed to finally address the contribution of enhanced surface expression of CXCR7 among platelets in this context. To conclude, the present results highlight a clinically relevant potential of platelet CXCR7 surface expression in mediating beneficial effects of SDF-1 on functional recovery in ACS patients. Understanding the role of platelets and platelet-derived CXCR7 in progenitor cell function and tissue regeneration might help further to assess the myocardial recovery potential after ACS and to develop novel therapeutic strategies for the treatment of patients with ischaemic heart disease. Further large-scale prospective studies are warranted to evaluate the role of platelet CXCR4/-7/ SDF-1 axis on clinical prognosis after ACSs in future.
